Trial Profile
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Amlitelimab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Kymab
- 25 Oct 2023 Results of safety and efficacy of amlitelimab for atopic dermatitis, published in the British Journal of Dermatology
- 18 Jul 2023 Results reporting safety and efficacy data over 16 weeks published in the British Journal of Dermatology
- 21 Mar 2023 Results assessing safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis presented at the American Academy of Dermatology annual Meeting 2023